CD4 and cancer: On the other hand, immunotherapy response differs between malignancies and within cancer Cohorts.[30] As a result, TMB levels were established to predict cancer patients’ response to immunotherapy, and high TMB has been demonstrated to correlate with immunotherapy efficacy.[31] CD4+, CD8 + T-cells and other antitumor immune cells were in negatively correlation with score, while cancer-associated fibroblasts (CAF) and the score were positive correlation, which may have interpreted the poor prognosis of HNSCC suffers.